Inflammatory cytokine receptors

Inflammatory cytokine receptors are a heterogeneous group of transmembrane proteins that serve as the primary sensors for signaling molecules such as IL-4, IL-8, IL-13, IL-17, TNF-alpha, and IFN-alpha. These receptors are categorized into several distinct families, including Type I and II cytokine receptors, the TNF receptor superfamily, and G protein-coupled receptors (GPCRs) for chemokines like IL-8 (UniProt P25024, P25025). Upon ligand binding, they activate complex intracellular pathways, most notably the JAK-STAT, NF-kappaB, and MAPK pathways, which orchestrate immune cell activation, recruitment, and survival (PubMed: 28473537). Dysregulation of these receptors is central to the pathogenesis of chronic inflammatory conditions, including asthma, rheumatoid arthritis, and systemic lupus erythematosus (PubMed: 30272097). Therapeutic targeting of these receptors—using monoclonal antibodies like dupilumab for IL-4Ralpha (UniProt P24394) or anifrolumab for IFNAR1 (UniProt P17181)—has revolutionized the treatment of autoimmune diseases by specifically neutralizing pro-inflammatory signaling. However, because these receptors are essential for host defense, their inhibition carries significant risks, including increased susceptibility to bacterial, viral, and fungal infections (StatPearls: Cytokine Antagonists).

Other names

Pro-inflammatory cytokine receptorsCytokine receptor superfamilyInflammatory mediator receptorsType I and II cytokine receptors

Competitive antagonism of ligand binding to the extracellular domain of the receptor, preventing the assembly of signaling complexes and subsequent activation of downstream pathways such as JAK-STAT or NF-kappaB.